pdf   xlsx method abbreviations

endometrial cancer, durvalumab based treatment versus chemotherapy, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.68 [0.52, 0.88]< 119%2 studies (2/-)99.8 %lownot evaluable highcrucial-
progression or deaths (PFS) 0.63 [0.49, 0.81]< 158%2 studies (2/-)100.0 %lownot evaluable highimportant-

safety endpoints 00

AE (any grade) 0.50 [0.02, 15.07]< 10%1 study (1/-)65.2 %NAnot evaluable non important-
AE (grade 3-5) 1.59 [1.09, 2.31]< 10%1 study (1/-)0.8 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 1.41 [0.90, 2.19]< 10%1 study (1/-)6.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons